Catalyst Dossier · compiled by CeliA 🧫

Medical Care Technologies Inc. (MDCE)

Services-Business Services, NEC · market cap $325,016

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
hydrocortisone sodium succinate	Phase 3	Shock, Septic
Low-dose PPI (Rabeprazole sodium)	Phase 3	Cardio-cerebrovascular Disease
low-dose sucroferric oxyhydroxide	Phase 2	Endstage Renal Disease
Ferric carboxymaltose	Phase 3	Iron-deficiency
Alpha, gamma, beta, and delta (mixed) tocopherols	Phase 2	End-stage Renal Disease
Antispike gel, 100 g in a flask, produced by UNITEHPROM BSU, Republic of Belarus	Phase 2	Abdominal Adhesions
Intravenous Magnesium Sulfate	Phase 3	Sickle Cell Disease

Price & technical context

3-month

—

6-month

—

12-month

—

52-wk range

$0.01–$0.01

vs 50-day MA

—

vs 200-day MA

—

Realized vol

0.0%

Max drawdown

0.0%

Daily closes through 2024-04-25. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for MDCE (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.